Share on StockTwits

Mirati Therapeutics (NASDAQ:MRTX) released its earnings data on Friday. The company reported ($0.82) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.69) by $0.13, Stock Ratings reports.

A number of research firms have recently commented on MRTX. Analysts at Johnson Rice upgraded shares of Mirati Therapeutics from an “overweight” rating to a “focus list” rating in a research note on Friday, July 11th. On a related note, analysts at Brean Capital initiated coverage on shares of Mirati Therapeutics in a research note on Tuesday, July 8th. They set a “buy” rating and a $27.00 price target on the stock. Finally, analysts at JMP Securities reiterated a “market outperform” rating on shares of Mirati Therapeutics in a research note on Monday, June 16th. They now have a $28.00 price target on the stock, up previously from $25.00. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Mirati Therapeutics currently has an average rating of “Buy” and an average target price of $29.67.

Mirati Therapeutics (NASDAQ:MRTX) traded down 4.24% on Friday, hitting $17.0362. The stock had a trading volume of 12,663 shares. Mirati Therapeutics has a 52 week low of $8.12 and a 52 week high of $25.97. The stock’s 50-day moving average is $18.8 and its 200-day moving average is $19.70. The company’s market cap is $229.6 million.

Receive News & Ratings for Mirati Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.